한글목차

아바스틴(베바시주맙)은 유전자 재조합 인간화 단클론성 IgG1 항체로, 혈관내피성장인자(VEGF)를 표적으로 하여 혈관신생억제제로 작용합니다. 베바시주맙은 내피세포 표면에 존재하는 VEGF의 수용체 VEGFR-1 및 VEGFR-2와 결합합니다. 이를 통해 VEGF의 활성을 감소시키고, 종양의 혈관 형성을 퇴행시키고, 종양 혈관 시스템을 정상화하고, 새로운 종양 혈관 시스템의 형성을 억제하여 종양의 성장을 방지할 수 있으며, VEGF는 다양한 질병, 특히 암에서 혈관 신생을 자극하는 화학적 신호입니다. 베바시주맙은 미국에서 임상적으로 사용 가능한 최초의 혈관신생 억제제입니다.

앞으로 수년간 다형성 교모세포종(GBM) 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 아바스틴의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, GBM에 대한 다른 신흥 제품들이 아바스틴과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

주요 7개국의 아바스틴 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 다형성교모세포종(GBM)에 대한 아바스틴의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 아바스틴 시장 평가

• GBM에 대한 아바스틴의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국의 GBM에 대한 아바스틴의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"AVASTIN Drug Insight and Market Forecast - 2032" report provides comprehensive insights about AVASTIN for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the AVASTIN for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the AVASTIN for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AVASTIN market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

AVASTIN (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps reduce VEGF activity and regress the vascularization of tumors, normalizing the tumor vasculature and inhibiting the formation of new tumor vasculature, thereby preventing tumor growth. VEGF is a chemical signal that stimulates angiogenesis in various diseases, especially cancer. Bevacizumab is the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under "Specialty drugs," only to be available through specialty pharmacies (under FDA's risk evaluation and mitigation strategy [REMS] program) (Genentech, n.d.). AVASTIN is indicated for treating GBM with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of AVASTIN in GBM is based on an improvement in objective response rate. No available data demonstrate any improvement in disease-related symptoms or increased survival with AVASTIN in GBM.

Dosage: 10 mg/kg IV every 2 weeks.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AVASTIN description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on AVASTIN regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AVASTIN research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AVASTIN.
• The report contains forecasted sales of AVASTIN for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for AVASTIN in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AVASTIN Analytical Perspective by DelveInsight

In-depth AVASTIN Market Assessment

This report provides a detailed market assessment of AVASTIN for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

AVASTIN Clinical Assessment

The report provides the clinical trials information of AVASTIN for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AVASTIN dominance.
• Other emerging products for GBM are expected to give tough market competition to AVASTIN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AVASTIN in GBM.
• Our in-depth analysis of the forecasted sales data of AVASTIN from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AVASTIN in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of AVASTIN?
• What is the clinical trial status of the study related to AVASTIN in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AVASTIN development?
• What are the key designations that have been granted to AVASTIN for GBM?
• What is the forecasted market scenario of AVASTIN for GBM?
• What are the forecasted sales of AVASTIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to AVASTIN for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. AVASTIN Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. AVASTIN Market Assessment

• 5.1. Market Outlook of AVASTIN in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of AVASTIN in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of AVASTIN in the United States for GBM
  • 5.3.2. Market Size of AVASTIN in Germany for GBM
  • 5.3.3. Market Size of AVASTIN in France for GBM
  • 5.3.4. Market Size of AVASTIN in Italy for GBM
  • 5.3.5. Market Size of AVASTIN in Spain for GBM
  • 5.3.6. Market Size of AVASTIN in the United Kingdom for GBM
  • 5.3.7. Market Size of AVASTIN in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options